Fig. 4 | Scientific Reports

Fig. 4

From: Autoantibody spark response predicts treatment outcome in patients receiving chemoradiation followed by durvalumab therapy

Fig. 4The alternative text for this image may have been generated using AI.

Stratification of patients based on autoantibody immune response and TPS. Patients were stratified by integrating SR/HSR immune monitoring levels and ICI efficacy prediction based on the TPS. (A) Swimmer plots illustrating events during the observation period for Group 1 (high immune induction: SR/HSR or TPS ≥ 50%) and Group 2 (low immune induction: w/o-SRs and TPS < 50%). (B) Kaplan‒Meier plots displaying PFS for Group 1 and Group 2 patients. The P value was derived from the log-rank test. SR spark response; HSR hyper-spark response, TPS tumor proportion score, CRT chemoradiotherapy, PFS progression-free survival, CI confidence interval.

Back to article page